Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Reducing SMM transformation risk: carfilzomib, lenalidomide & dexamethasone

Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, FL, discusses the results of a Phase II study (NCT01572480) of carfilzomib, lenalidomide and dexamethasone therapy as early intervention, followed by lenalidomide maintenance in high-risk smoldering multiple myeloma (SMM). The results show a favorable benefit-risk profile and warrant further investigation of the regimen in the SMM setting. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Consultancy: Adaptive, Amgen, Janssen, Glenmark, Celgene, Binding Site, BMS, Cellectis, Juno, Pfizer
Honoraria: Adaptive, Amgen, Janssen, Glenmark, Celgene, Binding Site, BMS, Cellectis, Juno, Pfizer
Research Funding: Amgen, Janssen, Takeda, Glenmark, Celgene, Seattle Genetics, Karyopharma
Independent Data Monitoring Committees for clinical trials: Janssen, Takeda
Other: Merck